Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-07-30Clinical Trial Update: ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas [Phase 3]
Phase 3 trial comparing Brentuximab Vedotin + CHP versus standard CHOP in CD30-positive mature T-cell lymphomas completed; results posted in…
-
FDA approval · 2019-07-23FDA Approved: RUXIENCE — Original Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved Ruxience (rituximab-pvvr) from Pfizer as a biosimilar to rituximab, under an original application; the approval covers multiple…
-
EMA withdrawal · 2019-07-08EMA Withdrawn: Rituzena (previously Tuxella) (rituximab) — Celltrion Healthcare Hungary Kft.
EMA withdrew Rituzena (rituximab) from the market (formerly Tuxella), with the decision dated 28 January 2019.
-
CLINICAL_TRIALS trial_result · 2019-06-28Clinical Trial Update: Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma Patients [Phase 2]
Phase 2 study of PQR309 in relapsed or refractory lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2019-06-14Clinical Trial Update: IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 trial of bendamustine, rituximab, and pixantrone in relapsed/refractory B-cell non-Hodgkin's lymphoma completed with posted results.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-06-14Clinical Trial Update: Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma [NA]
This clinical trial update reports on using etoposide, filgrastim, and plerixafor to improve stem cell mobilization in treating various non-…
-
FDA approval · 2019-05-30FDA Approved: MOZOBIL — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application for Mozobil (plerixafor) by Sanofi-Aventis U.S. LLC. The approval expands the indication to mobilize…
-
CLINICAL_TRIALS trial_result · 2019-05-29Clinical Trial Update: Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia [Phase 2]
Phase 2 clinical trial evaluating autologous peripheral blood stem cell transplant followed by donor bone marrow transplant in high-risk B- …
-
CLINICAL_TRIALS trial_result · 2019-05-28Clinical Trial Update: A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
Phase I/II trial of VELCADE (bortezomib) in combination with gemcitabine for relapsed or refractory aggressive B- and T-cell non-Hodgkin's l…
-
FDA approval · 2019-05-23FDA Approved: TRUXIMA — Supplemental Application (Cephalon, Inc.)
FDA approved a supplemental application for TRUXIMA (rituximab-ABBS) submitted by Cephalon, Inc.
-
CLINICAL_TRIALS trial_result · 2019-05-01Clinical Trial Update: Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies [Phase 2]
Phase 2 clinical trial evaluating BL-8040 for mobilizing donor hematopoietic stem cells to enable allogeneic transplantation in patients wit…
-
CLINICAL_TRIALS trial_result · 2019-04-17Clinical Trial Update: Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL) [Phase 1, Phase 2]
Clinical trial update on entospletinib plus vincristine in relapsed/refractory B-cell non-Hodgkin lymphoma; study terminated with posted res…
-
CLINICAL_TRIALS trial_result · 2019-04-16Clinical Trial Update: Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma [Phase 2]
Phase 2 trial evaluating ibrutinib in combination with rituximab in previously untreated follicular lymphoma shows completed status with pos…
-
CLINICAL_TRIALS trial_result · 2019-04-16Clinical Trial Update: CAR-T for R/R B-NHL [Phase 2]
A Phase 2 clinical trial update on CAR-T therapy targeting CD19/CD20/CD22/CD30 for relapsed or refractory non-Hodgkin lymphoma.
-
CLINICAL_TRIALS trial_result · 2019-04-02Clinical Trial Update: Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma [Phase 4]
Phase 4 clinical trial update evaluating polyethylene glycol liposome doxorubicin (PLD) for primary lymphoma (including Non-Hodgkin and Hodg…
-
CLINICAL_TRIALS trial_result · 2019-03-27Clinical Trial Update: Autologous and Allogeneic Transplant for Relapsed Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial update on autologous and allogeneic transplant for relapsed lymphoma, completed with results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-02-26Clinical Trial Update: Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies [Phase 1, Phase 2]
A pilot Phase 1/2 study evaluating safety and efficacy of NiCord and UNM CBU in patients with various hematologic malignancies has completed…
-
CLINICAL_TRIALS trial_result · 2019-02-15Clinical Trial Update: Trial of DA-EPOCH Regimen for NHL With HLH [Phase 2]
Phase 2 clinical trial update on the DA-EPOCH regimen for non-Hodgkin lymphoma with hemophagocytic lymphohistiocytosis; the current status i…
-
CLINICAL_TRIALS trial_result · 2019-02-04Clinical Trial Update: Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma [Phase 1]
The Phase 1 study of ET190L1 ARTEMIS T Cells in relapsed and refractory CD19+ non-Hodgkin lymphoma has been terminated.
-
CLINICAL_TRIALS trial_result · 2019-02-01Clinical Trial Update: Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
Clinical trial update for dasatinib in relapsed or refractory non-Hodgkin's lymphoma across Phase 1 and Phase 2, with completed status and r…
-
CLINICAL_TRIALS research · 2019-02-01Clinical Trial Update: A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHL [Phase 1]
Phase I trial evaluating AC0010 in patients with CLL/SLL, mantle cell lymphoma, diffuse large B-cell lymphoma, and other non-Hodgkin lymphom…
-
CLINICAL_TRIALS trial_result · 2019-01-18Clinical Trial Update: Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation [Phase 1]
Phase 1 trial evaluating inducible regulatory T cells (iTregs) in non-myeloablative sibling donor peripheral blood stem cell transplantation…
-
FDA approval · 2019-01-18FDA Approved: CYCLOPHOSPHAMIDE — Original Application (Cipla USA Inc.)
The FDA approved Cipla USA Inc.'s original application for a generic cyclophosphamide product. This marks approval of a generic formulation …
-
CLINICAL_TRIALS trial_result · 2019-01-07Clinical Trial Update: BuCE Versus BuME as Conditioning Therapy in Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial comparing BuCE to BuME as conditioning therapy in non-Hodgkin lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2019-01-04Clinical Trial Update: Busulfan, Melphalan and Etoposide as Conditioning for Autologous Transplantation for Non-Hodgkin's Lymphoma (NHL) [Phase 2]
Phase 2 trial evaluating a conditioning regimen (busulfan, melphalan, and etoposide) for autologous transplantation in non-Hodgkin's lymphom…